As of close of business last night, Apellis Pharmaceuticals Inc’s stock clocked out at $51.82, up 0.62% from its previous closing price of $51.50. On the day, 1007786 shares were traded.
Ratios:
To gain a deeper understanding of APLS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.50 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 05, 2024, Upgraded its rating to Buy and sets its target price to $80 from $68 previously.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $74.Goldman initiated its Buy rating on November 09, 2023, with a $74 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 08 ’24 when Deschatelets Pascal sold 69,107 shares for $54.17 per share. The transaction valued at 3,743,605 led to the insider holds 1,115,983 shares of the business.
Sullivan Timothy Eugene sold 4,000 shares of APLS for $234,640 on Apr 01 ’24. The Chief Financial Officer now owns 93,338 shares after completing the transaction at $58.66 per share. On Mar 19 ’24, another insider, Dunlop A. Sinclair, who serves as the Director of the company, sold 18,681 shares for $57.18 each. As a result, the insider received 1,068,161 and left with 173,998 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 15.76 while its Price-to-Book (P/B) ratio in mrq is 31.85.
Stock Price History:
Over the past 52 weeks, APLS has reached a high of $94.75, while it has fallen to a 52-week low of $19.83.
Shares Statistics:
A total of 119.56M shares are outstanding, with a floating share count of 98.84M. Insiders hold about 18.03% of the company’s shares, while institutions hold 91.84% stake in the company.
Earnings Estimates
As of right now, 12 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.88, while EPS last year was -$1.56. The consensus estimate for the next quarter is -$0.37, with high estimates of $0.09 and low estimates of -$0.6.
Analysts are recommending an EPS of between $0.46 and -$2.23 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is $1.2, with 11 analysts recommending between $2.28 and $0.13.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $161.28M. It ranges from a high estimate of $178.58M to a low estimate of $130.45M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $44.85M, an estimated increase of 259.60% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $187.99M, an increase of 167.60% less than the figure of $259.60% in the same quarter last year. There is a high estimate of $228.28M for the next quarter, whereas the lowest estimate is $162.63M.
A total of 14 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $919.78M, while the lowest revenue estimate was $712.95M, resulting in an average revenue estimate of $795.38M. In the same quarter a year ago, actual revenue was $396.59M, up 100.60% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.57B and the low estimate is $936.9M. The average revenue growth estimate for next year is up 48.60% from the average revenue estimate for this year.
